Scarica l'app Stockscreener
2.57
1.58%
0.04
Dopo l'orario di chiusura:
2.57
Precedente Chiudi:
$2.53
Aprire:
$2.53
Volume 24 ore:
513.42K
Relative Volume:
0.72
Capitalizzazione di mercato:
$81.10M
Reddito:
-
Utile/perdita netta:
$-69.00M
Rapporto P/E:
-0.9245
EPS:
-2.78
Flusso di cassa netto:
$-55.26M
1 W Prestazione:
+1.98%
1M Prestazione:
+14.73%
6M Prestazione:
+114.17%
1 anno Prestazione:
-63.60%
Intervallo 1D:
$2.4244
$2.605
Intervallo di 1 settimana:
$2.4244
$2.73
Portata 52W:
$1.05
$8.00
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Confronta ACRV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
2.57 | 79.83M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | Piper Sandler | Overweight |
| 2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-12-15 | Ripresa | Jefferies | Buy |
| 2023-10-05 | Iniziato | Maxim Group | Buy |
| 2023-06-02 | Iniziato | Oppenheimer | Outperform |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-04-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-12-12 | Iniziato | Jefferies | Buy |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Acrivon Therapeutics (NASDAQ:ACRV) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Holdings of Acrivon Therapeutics Inc (ACRV) are aligned with the stars - setenews.com
Volume Report: How Acrivon Therapeutics Inc stock reacts to bond yields2025 Historical Comparison & Growth-Oriented Investment Plans - moha.gov.vn
What drives Acrivon Therapeutics Inc stock priceTrendline Breakouts & Low Cost Capital Growth - earlytimes.in
SBI Cards and Payment Services Limited Stages Intraday Comeback Trend Change - earlytimes.in
How Acrivon Therapeutics Inc. stock reacts to bond yieldsBond Market & AI Forecasted Entry and Exit Points - Newser
ACRV SEC FilingsAcrivon Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Get in on Acrivon Therapeutics Inc’s (ACRV) buy-in window today! - setenews.com
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - Insider Monkey
Investors in cash trouble should check out Acrivon Therapeutics Inc (ACRV) - Setenews
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics' (ACRV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Chmn Blume-Jensen Surrenders 19,904 Of Acrivon Therapeutics Inc [ACRV] - TradingView
Citadel Advisors LLC Acquires Additional Shares in Acrivon Therapeutics Inc - GuruFocus
ACRV: HC Wainwright Reiterates 'Buy' Rating and $19 Price Target - GuruFocus
HC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation - Nasdaq
Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments - TipRanks
Acrivon insiders report RSU tax withholding, 2.05M shares held - Stock Titan
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - MarketBeat
Will Acrivon Therapeutics Inc. stock see PE expansionWeekly Trade Recap & High Accuracy Trade Alerts - newser.com
Research Analysts Issue Forecasts for ACRV FY2025 Earnings - Defense World
Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $11.00 - Defense World
There is no way Acrivon Therapeutics Inc (ACRV) can keep these numbers up - Setenews
Acrivon Therapeutics Form 4: COO tax withholding on 613 RSU shares - Stock Titan
Acrivon Therapeutics stock rating reiterated by Citizens with $13 target - Investing.com Nigeria
Is Acrivon Therapeutics Inc. stock attractive for hedge fundsMarket Performance Recap & Capital Efficient Trade Techniques - newser.com
Will Acrivon Therapeutics Inc. stock split attract more investors2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Acrivon Therapeutics Narrows Losses And Draws Analyst Support - Finimize
Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements - TipRanks
Acrivon Therapeutics Shrinks Losses And Draws Analyst Optimism - Finimize
Analysts’ Top Healthcare Picks: Acrivon Therapeutics, Inc. (ACRV), Sera Prognostics (SERA) - The Globe and Mail
Is Acrivon Therapeutics Inc. stock supported by strong cash flowsMarket Trend Report & Community Verified Watchlist Alerts - newser.com
Acrivon Therapeutics Reports Q3 2025 Financial Results - TipRanks
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):